Chlorthalidone Compared With HCTZ for MACE Reduction
To compare the clinical benefits of these diuretics, the study authors conducted a literature search that reported on outcomes such as MACE and left ventricular mass.
Thromboembolic Disorders
Narsoplimab Under Review for Stem Cell Transplant-Associated Thrombotic Microangiopathy
The FDA has accepted for filing and granted Priority Review to narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus
Rate of thrombotic events lower for patients with mean HCQ blood levels >1,068 versus <648 ng/mL
NSAID Use Among US Adults With Cardiovascular Disease Examined
Cross-sectional data from the National Health and Nutrition Examination Survey from 1988 to 1994 and 1999 to 2016 were used for this analysis.
MPR Weekly Dose Podcast Episode 61
This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has its approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.
Ongoing Anticoagulant Use Does Not Avert Severe COVID-19
No reduction seen in risks for hospital admission, intensive care unit admission, or death due to COVID
Tissue Factor Inhibitor Fast Tracked for COVID-19
AB201 is a small recombinant protein that selectively inhibits tissue factor, which has been shown to play a role in the inflammatory response associated with viral infections.
A Review of Treatments for HFrEF and Expert Q&A
Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients.
Brilinta Approved to Reduce Risk of Recurrent Stroke in High-Risk Patients
The approval was based on data from the phase 3 THALES trial (N=11,016) that compared treatment with ticagrelor plus aspirin to aspirin alone in preventing new stroke events.
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
